Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

Journal of the National Comprehensive Cancer Network : JNCCN - Tập 18 Số 11 - Trang 1537-1570 - 2020

Burt Nabors¹, Jana Portnow², Manmeet S. Ahluwalia³, Joachim M. Baehring⁴, Henry Brem⁵, Steven Brem⁶, Nicholas Butowski⁷, Jian L. Campian⁸, Stephen W. Clark⁹, Andrew J. Fabiano¹⁰, Peter Forsyth¹¹, Jona A. Hattangadi‐Gluth¹², Matthias Holdhoff⁵, Craig Horbinski¹³, Larry Junck¹⁴, Thomas Kaley¹⁵, Priya Kumthekar¹³, Jay S. Loeffler¹⁶, Maciej M. Mrugała¹⁷, Seema Nagpal¹⁸, Manjari Pandey¹⁹, Ian F. Parney¹⁷, Katherine B. Peters²⁰, Vinay K. Puduvalli²¹, Ian Robins²², Jason K. Rockhill²³, Chad G. Rusthoven²⁴, Nicole Shonka²⁵, Dennis C. Shrieve²⁶, Lode J. Swinnen⁵, Stephanie E. Weiss²⁷, Patrick Y. Wen²⁸, Nicole E. Willmarth²⁹, Mary Anne Bergman³⁰, Susan Darlow³⁰

¹1O'Neal Comprehensive Cancer Center at UAB;

²2City of Hope National Medical Center;

³3Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;

⁴4Yale Cancer Center/Smilow Cancer Hospital;

⁵5The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

⁶6Abramson Cancer Center at the University of Pennsylvania;

⁷7UCSF Helen Diller Family Comprehensive Cancer Center;

⁸8Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;

⁹Vanderbilt-Ingram Cancer Center; 10 Roswell Park Comprehensive Cancer Center;

¹⁰10Roswell Park Comprehensive Cancer Center;

¹¹11Moffitt Cancer Center;

¹²12UC San Diego Moores Cancer Center;

¹³13Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

¹⁴14University of Michigan Rogel Cancer Center;

¹⁵15Memorial Sloan Kettering Cancer Center;

¹⁶16Massachusetts General Hospital Cancer Center;

¹⁷17Mayo Clinic Cancer Center;

¹⁸18Stanford Cancer Institute;

¹⁹19St. Jude Children's Research Hospital/The University of Tennessee Health Science Center;

²⁰20Duke Cancer Institute;

²¹21The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;

²²22University of Wisconsin Carbone Cancer Center;

²³23Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;

²⁴University of Colorado Cancer Center; 25 Fred and Pamela Buffet Cancer Center;

²⁵25Fred and Pamela Buffet Cancer Center;

²⁶26Huntsman Cancer Institute at the University of Utah;

²⁷27Fox Chase Cancer Center;

²⁸28Dana-Farber Cancer Institute;

²⁹29American Brain Tumor Association; and

³⁰30National Comprehensive Cancer Network

Tóm tắt

The NCCN Guidelines for Central Nervous System (CNS) Cancers focus on management of adult CNS cancers ranging from noninvasive and surgically curable pilocytic astrocytomas to metastatic brain disease. The involvement of an interdisciplinary team, including neurosurgeons, radiation therapists, oncologists, neurologists, and neuroradiologists, is a key factor in the appropriate management of CNS cancers. Integrated histopathologic and molecular characterization of brain tumors such as gliomas should be standard practice. This article describes NCCN Guidelines recommendations for WHO grade I, II, III, and IV gliomas. Treatment of brain metastases, the most common intracranial tumors in adults, is also described.

Từ khóa

Tài liệu tham khảo

Norden, 2008, Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence, Neurology, 70, 779, 10.1212/01.wnl.0000304121.57857.38

Goldman, 2016, P2.36: Nivolumab (nivo) in patients (pts) with advanced (adv) NSCLC and central nervous system (CNS) metastases (mets), J Thorac Oncol, 11, S238, 10.1016/j.jtho.2016.08.107

Bell, 2018, Association of MGMT promoter methylation status with survival outcomes in patients with high-risk glioma treated with radiotherapy and temozolomide: an analysis from the NRG Oncology/RTOG 0424 trial, JAMA Oncol, 4, 1405, 10.1001/jamaoncol.2018.1977

Camidge, 2018, Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer, N Engl J Med, 379, 2027, 10.1056/NEJMoa1810171

Norden, 2008, Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence, Neurology, 70, 779, 10.1212/01.wnl.0000304121.57857.38

van den Bent, 2013, Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951, J Clin Oncol, 31, 344, 10.1200/JCO.2012.43.2229

Friedman, 2009, Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma, J Clin Oncol, 27, 4733, 10.1200/JCO.2008.19.8721

Hegi, 2005, MGMT gene silencing and benefit from temozolomide in glioblastoma, N Engl J Med, 352, 997, 10.1056/NEJMoa043331

Prados, 1989, Treatment of recurrent gliomas with 1,3-bis(2-chloroethyl)-1-nitrosourea and alpha-difluoromethylornithine, Neurosurgery, 24, 806, 10.1227/00006123-198906000-00003

Blumenthal, 2017, Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG, Neuro-oncol, 19, 1119, 10.1093/neuonc/nox025

Al-Omair, 2013, Hypofractionated stereotactic radiotherapy in five daily fractions for post-operative surgical cavities in brain metastases patients with and without prior whole brain radiation, Technol Cancer Res Treat, 12, 493, 10.7785/tcrt.2012.500336

Franz, 2013, Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial, Lancet, 381, 125, 10.1016/S0140-6736(12)61134-9

Vecht, 1993, Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery?, Ann Neurol, 33, 583, 10.1002/ana.410330605

BentMJ, 2019, van den Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without q codeletion Accessed Available at : https meetinglibrary asco org record, 19, 1

Ostrom, 2016, CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009-2013, Neuro-oncol, 18, v1, 10.1093/neuonc/now207

Higuchi, 2019, Stereotactic radiosurgery in elderly patients with brain metastases: comparison with non-elderly patients using database of a multi-institutional prospective observational study (JLGK0901-Elderly), J Neurooncol, 144, 393, 10.1007/s11060-019-03242-8

Stupp, 2012, NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality, Eur J Cancer, 48, 2192, 10.1016/j.ejca.2012.04.011

Wiestler, 2014, Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma, Acta Neuropathol, 128, 561, 10.1007/s00401-014-1315-x

Roa, 2004, Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial, J Clin Oncol, 22, 1583, 10.1200/JCO.2004.06.082

Davies, 2017, Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial, Lancet Oncol, 18, 863, 10.1016/S1470-2045(17)30429-1

Perry, 2010, Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study, J Clin Oncol, 28, 2051, 10.1200/JCO.2009.26.5520

Glas, 2009, Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide, J Clin Oncol, 27, 1257, 10.1200/JCO.2008.19.2195

Uppstrom, 2016, Repeat surgery for recurrent low-grade gliomas should be standard of care, Clin Neurol Neurosurg, 151, 18, 10.1016/j.clineuro.2016.09.013

Brown, 2017, Dabrafenib and trametinib in BRAFV600E mutated glioma, CNS Oncol, 6, 291, 10.2217/cns-2017-0006

Kaley, 2013, Bevacizumab for acute neurologic deterioration in patients with glioblastoma, CNS Oncol, 2, 413, 10.2217/cns.13.40

Doebele, 2020, Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials, Lancet Oncol, 21, 271, 10.1016/S1470-2045(19)30691-6

Chen, 2017, Use of stereotactic radiosurgery in elderly and very elderly patients with brain metastases to limit toxicity associated with whole brain radiation therapy, Int J Radiat Oncol Biol Phys, 98, 939, 10.1016/j.ijrobp.2017.02.031

Sampson, 2015, Alternating electric fields for the treatment of glioblastoma, JAMA, 314, 2511, 10.1001/jama.2015.16701

Horbinski, 2012, Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas, Neuro-oncol, 14, 777, 10.1093/neuonc/nos077

Minniti, 2016, Single-fraction versus multifraction (3 x 9 Gy) stereotactic radiosurgery for large (>2 cm) brain metastases: a comparative analysis of local control and risk of radiation-induced brain necrosis, Int J Radiat Oncol Biol Phys, 95, 1142, 10.1016/j.ijrobp.2016.03.013

Berger, 1994, The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas, Cancer, 74, 1784, 10.1002/1097-0142(19940915)74:6<1784::AID-CNCR2820740622>3.0.CO;2-D

Aoyama, 2006, Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial, JAMA, 295, 2483, 10.1001/jama.295.21.2483

Triebels, 2004, Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas, Neurology, 63, 904, 10.1212/01.WNL.0000137049.65631.DB

Raman, 2020, Whole brain radiotherapy versus stereotactic radiosurgery in poor-prognosis patients with one to 10 brain metastases: a randomised feasibility study, Clin Oncol (R Coll Radiol), 32, 442, 10.1016/j.clon.2020.02.001

Hegi, 2004, Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide, Clin Cancer Res, 10, 1871, 10.1158/1078-0432.CCR-03-0384

Ding, 2009, Dosimetric comparison between 3DCRT and IMRT using different multileaf collimators in the treatment of brain tumors, Med Dosim, 34, 1, 10.1016/j.meddos.2007.04.001

Stupp, 2005, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N Engl J Med, 352, 987, 10.1056/NEJMoa043330

Coburger, 2019, Fluorescence guided surgery by 5-ALA and intraoperative MRI in high grade glioma: a systematic review, J Neurooncol, 141, 533, 10.1007/s11060-018-03052-4

Arita, 2013, Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss, Acta Neuropathol, 126, 267, 10.1007/s00401-013-1141-6

Stupp, 2014, Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial, Lancet Oncol, 15, 1100, 10.1016/S1470-2045(14)70379-1

Labussière, 2010, All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2, Neurology, 74, 1886, 10.1212/WNL.0b013e3181e1cf3a

Brown, 2013, Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial, Neuro-oncol, 15, 1429, 10.1093/neuonc/not114

Pignatti, 2002, Prognostic factors for survival in adult patients with cerebral low-grade glioma, J Clin Oncol, 20, 2076, 10.1200/JCO.2002.08.121

Shaw, 2000, Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05, Int J Radiat Oncol Biol Phys, 47, 291, 10.1016/S0360-3016(99)00507-6

Lombardi, 2019, Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial, Lancet Oncol, 20, 110, 10.1016/S1470-2045(18)30675-2

Andrews, 2004, Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial, Lancet, 363, 1665, 10.1016/S0140-6736(04)16250-8

Roth, 2013, Subependymal giant cell astrocytoma: diagnosis, screening, and treatment. Recommendations from the International Tuberous Sclerosis Complex Consensus Conference 2012, Pediatr Neurol, 49, 439, 10.1016/j.pediatrneurol.2013.08.017

Churilla, 2017, Whole brain radiotherapy after stereotactic radiosurgery or surgical resection among patients with one to three brain metastases and favorable prognoses: a secondary analysis of EORTC 22952-26001, Ann Oncol, 28, 2588, 10.1093/annonc/mdx332

Barnholtz-Sloan, 2004, Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System, J Clin Oncol, 22, 2865, 10.1200/JCO.2004.12.149

Suh, 2010, Stereotactic radiosurgery for the management of brain metastases, N Engl J Med, 362, 1119, 10.1056/NEJMct0806951

Brown, 2017, Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial, Lancet Oncol, 18, 1049, 10.1016/S1470-2045(17)30441-2

Nahed, 2015, Management of patients with recurrence of diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline, J Neurooncol, 125, 609, 10.1007/s11060-015-1910-2

Killela, 2013, TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal, Proc Natl Acad Sci USA, 110, 6021, 10.1073/pnas.1303607110

Ameratunga, 2018, Anti-angiogenic therapy for high-grade glioma, Cochrane Database Syst Rev, 11, CD008218

Vredenburgh, 2007, Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma, Clin Cancer Res, 13, 1253, 10.1158/1078-0432.CCR-06-2309

Wick, 2017, Lomustine and bevacizumab in progressive glioblastoma, N Engl J Med, 377, 1954, 10.1056/NEJMoa1707358

Lo, 2003, Radiation dose response for supratentorial low-grade glioma--institutional experience and literature review, J Neurol Sci, 214, 43, 10.1016/S0022-510X(03)00181-3

Camidge, 2018, Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer, N Engl J Med, 379, 2027, 10.1056/NEJMoa1810171

Penman, 2015, Current understanding of BRAF alterations in diagnosis, prognosis, and therapeutic targeting in pediatric low-grade gliomas, Front Oncol, 5, 54, 10.3389/fonc.2015.00054

Schiff, 2019, Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus, Neuro-oncol, 21, 837, 10.1093/neuonc/noz033

Franz, 2010, Tuberous sclerosis complex: neurological, renal and pulmonary manifestations, Neuropediatrics, 41, 199, 10.1055/s-0030-1269906

Schouten, 2002, Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma, Cancer, 94, 2698, 10.1002/cncr.10541

Marks, 2018, Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib, Pediatr Blood Cancer, 65, e26969, 10.1002/pbc.26969

Tang, 2019, Comparative assessment of the efficacy of gross total versus subtotal total resection in patients with glioma: a meta-analysis, Int J Surg, 63, 90, 10.1016/j.ijsu.2019.02.004

Bhatnagar, 2006, Stereotactic radiosurgery for four or more intracranial metastases, Int J Radiat Oncol Biol Phys, 64, 898, 10.1016/j.ijrobp.2005.08.035

Ramakrishna, 2015, Outcomes in reoperated low-grade gliomas, Neurosurgery, 77, 175, 10.1227/NEU.0000000000000753

Sheehan, 2005, Radiosurgery for patients with recurrent small cell lung carcinoma metastatic to the brain: outcomes and prognostic factors, J Neurosurg, 102, 247, 10.3171/sup.2005.102.s_supplement.0247

Cloughesy, 2008, A phase 2 randomized non-comparative clinical trial of the effect of bevacizumab alone or in combination with irinotecan on 6-month progression free survival in recurrent refractory glioblastoma. [abstract], J Clin Oncol, 26, 2010b, 10.1200/jco.2008.26.15_suppl.2010b

Tawbi, 2018, Combined nivolumab and ipilimumab in melanoma metastatic to the brain, N Engl J Med, 379, 722, 10.1056/NEJMoa1805453

Horbinski, 2013, What do we know about IDH1/2 mutations so far, and how do we use it?, Acta Neuropathol, 125, 621, 10.1007/s00401-013-1106-9

Hawkins, 2011, BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma, Clin Cancer Res, 17, 4790, 10.1158/1078-0432.CCR-11-0034

Pekmezci, 2017, Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT, Acta Neuropathol, 133, 1001, 10.1007/s00401-017-1690-1

Shaw, 2002, Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study, J Clin Oncol, 20, 2267, 10.1200/JCO.2002.09.126

Fink, 2011, Pseudoprogression: relevance with respect to treatment of high-grade gliomas, Curr Treat Options Oncol, 12, 240, 10.1007/s11864-011-0157-1

Weller, 2019, Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial, Lancet Oncol, 20, 1444, 10.1016/S1470-2045(19)30502-9

Yung, 2000, A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse, Br J Cancer, 83, 588, 10.1054/bjoc.2000.1316

Sanson, 2009, Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas, J Clin Oncol, 27, 4150, 10.1200/JCO.2009.21.9832

Finazzi, 2016, One week of radiotherapy for glioblastoma: a noninferiority trial?, J Clin Oncol, 34, 2192, 10.1200/JCO.2015.65.7783

Ebrahimi-Fakhari, 2020, Pharmacological treatment strategies for subependymal giant cell astrocytoma (SEGA), Expert Opin Pharmacother, 21, 1329, 10.1080/14656566.2020.1751124

Finazzi, 2016, One week of radiotherapy for glioblastoma: a noninferiority trial?, J Clin Oncol, 34, 2192, 10.1200/JCO.2015.65.7783

Cairncross, 2014, Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH, J Clin Oncol, 32, 783, 10.1200/JCO.2013.49.3726

Sturm, 2012, Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma, Cancer Cell, 22, 425, 10.1016/j.ccr.2012.08.024

Brem, 1995, Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas, Lancet, 345, 1008, 10.1016/S0140-6736(95)90755-6

Ida, 2015, Pleomorphic xanthoastrocytoma: natural history and long-term follow-up, Brain Pathol, 25, 575, 10.1111/bpa.12217

Soffietti, 1998, PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas, Neurosurgery, 43, 1066, 10.1097/00006123-199811000-00035

Patchell, 1998, Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial, JAMA, 280, 1485, 10.1001/jama.280.17.1485

Goss, 2016, Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study, Lancet Oncol, 17, 1643, 10.1016/S1470-2045(16)30508-3

Nabors, 2015, Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study, Neuro-oncol, 17, 708, 10.1093/neuonc/nou356

van den Bent, 2017, Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study, Lancet, 390, 1645, 10.1016/S0140-6736(17)31442-3

Brat, 2020, cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas, Acta Neuropathol, 139, 603, 10.1007/s00401-020-02127-9

Brandes, 2008, MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients, J Clin Oncol, 26, 2192, 10.1200/JCO.2007.14.8163

Indelicato, 2019, Outcomes following proton therapy for pediatric low-grade glioma, Int J Radiat Oncol Biol Phys, 104, 149, 10.1016/j.ijrobp.2019.01.078

Perry, 2008, Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the “rescue” approach, Cancer, 113, 2152, 10.1002/cncr.23813

Vredenburgh, 2007, Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma, Clin Cancer Res, 13, 1253, 10.1158/1078-0432.CCR-06-2309

Skalicky, 2015, The burden of subependymal giant cell astrocytomas associated with tuberous sclerosis complex: results of a patient and caregiver survey, J Child Neurol, 30, 563, 10.1177/0883073814523318

Pekmezci, 2017, Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT, Acta Neuropathol, 133, 1001, 10.1007/s00401-017-1690-1

Tang, 2019, Comparative assessment of the efficacy of gross total versus subtotal total resection in patients with glioma: a meta-analysis, Int J Surg, 63, 90, 10.1016/j.ijsu.2019.02.004

Tahiri Elousrouti, 2016, Subependymal giant cell astrocytoma (SEGA): a case report and review of the literature, J Med Case Reports, 10, 35, 10.1186/s13256-016-0818-6

Malmström, 2012, Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial, Lancet Oncol, 13, 916, 10.1016/S1470-2045(12)70265-6

Gorovets, 2012, IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma, Clin Cancer Res, 18, 2490, 10.1158/1078-0432.CCR-11-2977

Molinaro, 2020, Association of maximal extent of resection of contrast-enhanced and non-contrast-enhanced tumor with survival within molecular subgroups of patients with newly diagnosed glioblastoma, JAMA Oncol, 6, 495, 10.1001/jamaoncol.2019.6143

Goldman, 2016, P2.36: Nivolumab (nivo) in patients (pts) with advanced (adv) NSCLC and central nervous system (CNS) metastases (mets), J Thorac Oncol, 11, S238, 10.1016/j.jtho.2016.08.107

Herrlinger, 2019, Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial, Lancet, 393, 678, 10.1016/S0140-6736(18)31791-4

Arita, 2016, A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas, Acta Neuropathol Commun, 4, 79, 10.1186/s40478-016-0351-2

Maher, 2009, Brain metastasis: opportunities in basic and translational research, Cancer Res, 69, 6015, 10.1158/0008-5472.CAN-08-4347

van den Bent, 2017, Diffuse infiltrating oligodendroglioma and astrocytoma, J Clin Oncol, 35, 2394, 10.1200/JCO.2017.72.6737

Hong, 2020, Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials, Lancet Oncol, 21, 531, 10.1016/S1470-2045(19)30856-3

Dubbink, 2016, Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial, Neuro-oncol, 18, 388, 10.1093/neuonc/nov182

Chapman, 2011, Improved survival with vemurafenib in melanoma with BRAF V600E mutation, N Engl J Med, 364, 2507, 10.1056/NEJMoa1103782

Lin, 2004, CNS metastases in breast cancer, J Clin Oncol, 22, 3608, 10.1200/JCO.2004.01.175

Olar, 2015, IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas, Acta Neuropathol, 129, 585, 10.1007/s00401-015-1398-z

Jackson, 2001, Limitations of stereotactic biopsy in the initial management of gliomas, Neuro-oncol, 3, 193, 10.1093/neuonc/3.3.193

Mahajan, 2017, Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial, Lancet Oncol, 18, 1040, 10.1016/S1470-2045(17)30414-X

Weller, 2015, Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups, Acta Neuropathol, 129, 679, 10.1007/s00401-015-1409-0

Brat, 2015, Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas, N Engl J Med, 372, 2481, 10.1056/NEJMoa1402121

Taphoorn, 2018, Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized clinical trial, JAMA Oncol, 4, 495, 10.1001/jamaoncol.2017.5082

Soria, 2018, Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer, N Engl J Med, 378, 113, 10.1056/NEJMoa1713137

Piepmeier, 1996, Variations in the natural history and survival of patients with supratentorial low-grade astrocytomas, Neurosurgery, 38, 872, 10.1097/00006123-199605000-00002

Gorlia, 2013, New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III clinical trials, Neuro-oncol, 15, 1568, 10.1093/neuonc/not117

Beiko, 2014, IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection, Neuro-oncol, 16, 81, 10.1093/neuonc/not159

Soliman, 2018, Consensus contouring guidelines for postoperative completely resected cavity stereotactic radiosurgery for brain metastases, Int J Radiat Oncol Biol Phys, 100, 436, 10.1016/j.ijrobp.2017.09.047

Kazmi, 2019, Re-irradiation for recurrent glioblastoma (GBM): a systematic review and meta-analysis, J Neurooncol, 142, 79, 10.1007/s11060-018-03064-0

Yomo, 2016, Is upfront stereotactic radiosurgery a rational treatment option for very elderly patients with brain metastases? A retrospective analysis of 106 consecutive patients age 80 years and older, BMC Cancer, 16, 948, 10.1186/s12885-016-2983-9

Adriaensen, 2009, Prevalence of subependymal giant cell tumors in patients with tuberous sclerosis and a review of the literature, Eur J Neurol, 16, 691, 10.1111/j.1468-1331.2009.02567.x

Kased, 2009, Gamma knife radiosurgery for brain metastases from primary breast cancer, Int J Radiat Oncol Biol Phys, 75, 1132, 10.1016/j.ijrobp.2008.12.031

Korshunov, 2016, Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity, Acta Neuropathol, 131, 137, 10.1007/s00401-015-1493-1

Gould, 2018, Breaking down the epidemiology of brain cancer, Nature, 561, S40, 10.1038/d41586-018-06704-7

Roelz, 2016, Residual tumor volume as best outcome predictor in low grade glioma - a nine-years near-randomized survey of surgery vs biopsy, Sci Rep, 6, 32286, 10.1038/srep32286

Wahl, 2017, Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide, Neuro-oncol, 19, 242

Kreisl, 2009, Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma, J Clin Oncol, 27, 740, 10.1200/JCO.2008.16.3055

Roa, 2015, International Atomic Energy Agency randomized phase III study of radiation therapy in elderly and/or frail patients with newly diagnosed glioblastoma multiforme, J Clin Oncol, 33, 4145, 10.1200/JCO.2015.62.6606

Banfill, 2012, Stereotactic radiosurgery for the treatment of brain metastases: impact of cerebral disease burden on survival, Br J Neurosurg, 26, 674, 10.3109/02688697.2012.690913

Hegi, 2005, MGMT gene silencing and benefit from temozolomide in glioblastoma, N Engl J Med, 352, 997, 10.1056/NEJMoa043331

Houillier, 2010, IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas, Neurology, 75, 1560, 10.1212/WNL.0b013e3181f96282

Fink, 2011, Pseudoprogression: relevance with respect to treatment of high-grade gliomas, Curr Treat Options Oncol, 12, 240, 10.1007/s11864-011-0157-1

Noël, 2001, Radiosurgery for re-irradiation of brain metastasis: results in 54 patients, Radiother Oncol, 60, 61, 10.1016/S0167-8140(01)00359-0

JaeckleKA, 2020, den phase III study of RT RT temozolomide or TMZ for newly diagnosed q codeleted oligodendroglioma Analysis from the initial study design Accessed Available at https www ncbi nlm nih gov pubmed, 19, 1

McGirt, 2008, Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas, Neurosurgery, 63, 700, 10.1227/01.NEU.0000325729.41085.73

Patchell, 1990, A randomized trial of surgery in the treatment of single metastases to the brain, N Engl J Med, 322, 494, 10.1056/NEJM199002223220802

Wahl, 2017, Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide, Neuro-oncol, 19, 242

Gilbert, 2013, Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial, J Clin Oncol, 31, 4085, 10.1200/JCO.2013.49.6968

Kleinschmidt-DeMasters, 2013, Epithelioid GBMs show a high percentage of BRAF V600E mutation, Am J Surg Pathol, 37, 685, 10.1097/PAS.0b013e31827f9c5e

Ewend, 2008, Guidelines for the initial management of metastatic brain tumors: role of surgery, radiosurgery, and radiation therapy, J Natl Compr Canc Netw, 6, 505, 10.6004/jnccn.2008.0038

Balana, A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond six cycles in patients with glioblastoma (GEINO 14-01) [published online April 24, 2020], Neuro Oncol

Ellingson, 2017, Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape, J Neurooncol, 134, 495, 10.1007/s11060-017-2375-2

Horbinski, 2013, To BRAF or not to BRAF: is that even a question anymore?, J Neuropathol Exp Neurol, 72, 2, 10.1097/NEN.0b013e318279f3db

Wick, 2012, Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial, Lancet Oncol, 13, 707, 10.1016/S1470-2045(12)70164-X

Nitta, 2015, Proposed therapeutic strategy for adult low-grade glioma based on aggressive tumor resection, Neurosurg Focus, 38, E7, 10.3171/2014.10.FOCUS14651

Ramakrishna, 2015, Outcomes in reoperated low-grade gliomas, Neurosurgery, 77, 175, 10.1227/NEU.0000000000000753

Suh, 2010, Stereotactic radiosurgery for the management of brain metastases, N Engl J Med, 362, 1119, 10.1056/NEJMct0806951

Cairncross, 2006, Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402, J Clin Oncol, 24, 2707, 10.1200/JCO.2005.04.3414

Shaw, 1989, Radiation therapy in the management of low-grade supratentorial astrocytomas, J Neurosurg, 70, 853, 10.3171/jns.1989.70.6.0853

Sturm, 2012, Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma, Cancer Cell, 22, 425, 10.1016/j.ccr.2012.08.024

Louis, 2016, The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary, Acta Neuropathol, 131, 803, 10.1007/s00401-016-1545-1

WenPY, 2020, Glioblastoma in adults a for - European of - consensus on current management and future directions Accessed Available at https www ncbi nlm nih gov pubmed, Society Oncology Society Oncology review, 26

Fox, 2011, Epidemiology of metastatic brain tumors, Neurosurg Clin N Am, 22, 1, 10.1016/j.nec.2010.08.007

Möllemann, 2005, Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors, Int J Cancer, 113, 379, 10.1002/ijc.20575

Akyurek, 2007, Stereotactic radiosurgical treatment of cerebral metastases arising from breast cancer, Am J Clin Oncol, 30, 310, 10.1097/01.coc.0000258365.50975.f6

Saura, 2019, Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: findings from the multinational, randomized, phase III NALA trial, J Clin Oncol, 37, 1002, 10.1200/JCO.2019.37.15_suppl.1002

Wick, 2016, Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide, Neuro-oncol, 18, 1529

Gould, 2018, Breaking down the epidemiology of brain cancer, Nature, 561, S40, 10.1038/d41586-018-06704-7

Park, 2010, Scale to predict survival after surgery for recurrent glioblastoma multiforme, J Clin Oncol, 28, 3838, 10.1200/JCO.2010.30.0582

Gondi, 2014, Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial, J Clin Oncol, 32, 3810, 10.1200/JCO.2014.57.2909

Nicholson, 2007, Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children’s Oncology Group, Cancer, 110, 1542, 10.1002/cncr.22961

Mohammadi, 2014, Use of high-field intraoperative magnetic resonance imaging to enhance the extent of resection of enhancing and nonenhancing gliomas, Neurosurgery, 74, 339, 10.1227/NEU.0000000000000278

Kristensen, 2019, Molecular pathology of tumors of the central nervous system, Ann Oncol, 30, 1265, 10.1093/annonc/mdz164

Brandes, 2006, Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma, Neuro-oncol, 8, 253, 10.1215/15228517-2006-005

Stupp, 2017, Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial, JAMA, 318, 2306, 10.1001/jama.2017.18718

Goh, 2004, Subependymal giant cell tumors in tuberous sclerosis complex, Neurology, 63, 1457, 10.1212/01.WNL.0000142039.14522.1A

Taal, 2014, Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial, Lancet Oncol, 15, 943, 10.1016/S1470-2045(14)70314-6

Sahm, 2014, Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma, Acta Neuropathol, 128, 551, 10.1007/s00401-014-1326-7

Levin, 1990, Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report, Int J Radiat Oncol Biol Phys, 18, 321, 10.1016/0360-3016(90)90096-3

McGirt, 2010, Carmustine wafers (Gliadel) plus concomitant temozolomide therapy after resection of malignant astrocytoma: growing evidence for safety and efficacy, Ann Surg Oncol, 17, 1729, 10.1245/s10434-010-1092-2

Eckel-Passow, 2015, Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors, N Engl J Med, 372, 2499, 10.1056/NEJMoa1407279

Minniti, 2015, Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis, Int J Radiat Oncol Biol Phys, 91, 109, 10.1016/j.ijrobp.2014.09.013

Goh, 2004, Subependymal giant cell tumors in tuberous sclerosis complex, Neurology, 63, 1457, 10.1212/01.WNL.0000142039.14522.1A

Neumann, 2016, Distinct histomorphology in molecular subgroups of glioblastomas in young patients, J Neuropathol Exp Neurol, 75, 408, 10.1093/jnen/nlw015

Freedman, 2019, TBCRC 022: a phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases, J Clin Oncol, 37, 1081, 10.1200/JCO.18.01511

van den Bent, 2017, Diffuse infiltrating oligodendroglioma and astrocytoma, J Clin Oncol, 35, 2394, 10.1200/JCO.2017.72.6737

Cairncross, 2013, Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402, J Clin Oncol, 31, 337, 10.1200/JCO.2012.43.2674

Reithmeier, 2010, BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors, BMC Cancer, 10, 30, 10.1186/1471-2407-10-30

Prados, 1989, Treatment of recurrent gliomas with 1,3-bis(2-chloroethyl)-1-nitrosourea and alpha-difluoromethylornithine, Neurosurgery, 24, 806, 10.1227/00006123-198906000-00003

Yang, 2018, Biopsy versus subtotal versus gross total resection in patients with low-grade glioma: a systematic review and meta-analysis, World Neurosurg, 120, e762, 10.1016/j.wneu.2018.08.163

Ewend, 2008, Guidelines for the initial management of metastatic brain tumors: role of surgery, radiosurgery, and radiation therapy, J Natl Compr Canc Netw, 6, 505, 10.6004/jnccn.2008.0038

Mintz, 1996, A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis, Cancer, 78, 1470, 10.1002/(SICI)1097-0142(19961001)78:7<1470::AID-CNCR14>3.0.CO;2-X

Hanson, 2012, A concise review of the efficacy of stereotactic radiosurgery in the management of melanoma and renal cell carcinoma brain metastases, World J Surg Oncol, 10, 176, 10.1186/1477-7819-10-176

Arevalo, 2019, Assessment of glioblastoma response in the era of bevacizumab: longstanding and emergent challenges in the imaging evaluation of pseudoresponse, Front Neurol, 10, 460, 10.3389/fneur.2019.00460

Cabrera, 2016, Radiation therapy for glioblastoma: executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline, Pract Radiat Oncol, 6, 217, 10.1016/j.prro.2016.03.007

Chamberlain, 2009, Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma, Cancer, 115, 1734, 10.1002/cncr.24179

Kreisl, 2009, Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma, J Clin Oncol, 27, 740, 10.1200/JCO.2008.16.3055

Brown, 2019, Management of low-grade glioma: a systematic review and meta-analysis, Neurooncol Pract, 6, 249

Jiao, 2012, Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas, Oncotarget, 3, 709, 10.18632/oncotarget.588

Wick, 2010, Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma, J Clin Oncol, 28, 1168, 10.1200/JCO.2009.23.2595

Gandhi, 2017, Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: comparison of RECIST 1.1 and RANO-HGG criteria, Eur J Cancer, 82, 27, 10.1016/j.ejca.2017.05.019

Brown, 2016, Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial, JAMA, 316, 401, 10.1001/jama.2016.9839

Noël, 2001, Radiosurgery for re-irradiation of brain metastasis: results in 54 patients, Radiother Oncol, 60, 61, 10.1016/S0167-8140(01)00359-0

Yung, 2000, A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse, Br J Cancer, 83, 588, 10.1054/bjoc.2000.1316

Perry, 2010, Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study, J Clin Oncol, 28, 2051, 10.1200/JCO.2009.26.5520

Mistry, 2015, BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma, J Clin Oncol, 33, 1015, 10.1200/JCO.2014.58.3922

Lo, 2001, Does the extent of surgery have an impact on the survival of patients who receive postoperative radiation therapy for supratentorial low-grade gliomas?, Int J Cancer, 96, 71, 10.1002/ijc.10359

Chamberlain, 2009, Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma, J Neurooncol, 91, 359, 10.1007/s11060-008-9722-2

Reuss, 2015, ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma, Acta Neuropathol, 129, 133, 10.1007/s00401-014-1370-3

Daniels, 2011, Validation of EORTC prognostic factors for adults with low-grade glioma: a report using intergroup 86-72-51, Int J Radiat Oncol Biol Phys, 81, 218, 10.1016/j.ijrobp.2010.05.003

Soltys, 2015, A phase I/II dose-escalation trial of 3-fraction stereotactic radiosurgery (SRS) for large resection cavities of brain metastases, Int J Radiat Oncol Biol Phys, 93, S38, 10.1016/j.ijrobp.2015.07.093

Stupp, 2005, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N Engl J Med, 352, 987, 10.1056/NEJMoa043330

Labussière, 2010, All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2, Neurology, 74, 1886, 10.1212/WNL.0b013e3181e1cf3a

Weller, 2015, MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR trial, Clin Cancer Res, 21, 2057, 10.1158/1078-0432.CCR-14-2737

Tawbi, 2018, Combined nivolumab and ipilimumab in melanoma metastatic to the brain, N Engl J Med, 379, 722, 10.1056/NEJMoa1805453

Kiliç, 2002, Effect of surgery on tumor progression and malignant degeneration in hemispheric diffuse low-grade astrocytomas, J Clin Neurosci, 9, 549, 10.1054/jocn.2002.1136

Barker, 1998, Survival and functional status after resection of recurrent glioblastoma multiforme, Neurosurgery, 42, 709, 10.1097/00006123-199804000-00013

Pai, 2017, Histological spectrum of oligodendroglial tumors: Only a subset shows 1p/19q codeletion, Neurol India, 65, 113, 10.4103/0028-3886.198195

Nitta, 2015, Proposed therapeutic strategy for adult low-grade glioma based on aggressive tumor resection, Neurosurg Focus, 38, E7, 10.3171/2014.10.FOCUS14651

Murthy, 2020, Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer, N Engl J Med, 382, 597, 10.1056/NEJMoa1914609

Chang, 2017, Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813, Neuro-oncol, 19, 252

Hong, 2019, Adjuvant whole-brain radiation therapy compared with observation after local treatment of melanoma brain metastases: a multicenter, randomized phase III trial, J Clin Oncol, 37, 3132, 10.1200/JCO.19.01414

Cairncross, 2014, Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH, J Clin Oncol, 32, 783, 10.1200/JCO.2013.49.3726

Murthy, 2020, Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer, N Engl J Med, 382, 597, 10.1056/NEJMoa1914609

Carvalho, 2015, Second-line chemotherapy in recurrent glioblastoma: a 2-cohort study, Oncol Res Treat, 38, 348, 10.1159/000431236

Yang, 2018, Biopsy versus subtotal versus gross total resection in patients with low-grade glioma: a systematic review and meta-analysis, World Neurosurg, 120, e762, 10.1016/j.wneu.2018.08.163

Yamamoto, 2014, Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study, Lancet Oncol, 15, 387, 10.1016/S1470-2045(14)70061-0

Kim, 2016, Too little, too soon: short-course radiotherapy in elderly patients with glioblastoma, J Clin Oncol, 34, 2191, 10.1200/JCO.2015.66.3195

Franz, 2010, Tuberous sclerosis complex: neurological, renal and pulmonary manifestations, Neuropediatrics, 41, 199, 10.1055/s-0030-1269906

Wick, 2016, Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide, Neuro-oncol, 18, 1529

Kaley, 2013, Bevacizumab for acute neurologic deterioration in patients with glioblastoma, CNS Oncol, 2, 413, 10.2217/cns.13.40

Glas, 2009, Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide, J Clin Oncol, 27, 1257, 10.1200/JCO.2008.19.2195

Neumann, 2016, Distinct histomorphology in molecular subgroups of glioblastomas in young patients, J Neuropathol Exp Neurol, 75, 408, 10.1093/jnen/nlw015

Baumert, 2016, Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study, Lancet Oncol, 17, 1521, 10.1016/S1470-2045(16)30313-8

Horbinski, 2013, What do we know about IDH1/2 mutations so far, and how do we use it?, Acta Neuropathol, 125, 621, 10.1007/s00401-013-1106-9

Schmidt, 2006, PCV chemotherapy for recurrent glioblastoma, Neurology, 66, 587, 10.1212/01.wnl.0000197792.73656.c2

Brandes, 2004, How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial, Neurology, 63, 1281, 10.1212/01.WNL.0000140495.33615.CA

Mok, 2017, Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer, N Engl J Med, 376, 629, 10.1056/NEJMoa1612674

Cairncross, 2013, Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402, J Clin Oncol, 31, 337, 10.1200/JCO.2012.43.2674

Roa, 2004, Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial, J Clin Oncol, 22, 1583, 10.1200/JCO.2004.06.082

Goldberg, 2016, Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial, Lancet Oncol, 17, 976, 10.1016/S1470-2045(16)30053-5

Yan, 2009, IDH1 and IDH2 mutations in gliomas, N Engl J Med, 360, 765, 10.1056/NEJMoa0808710

Kiliç, 2002, Effect of surgery on tumor progression and malignant degeneration in hemispheric diffuse low-grade astrocytomas, J Clin Neurosci, 9, 549, 10.1054/jocn.2002.1136

Patchell, 1990, A randomized trial of surgery in the treatment of single metastases to the brain, N Engl J Med, 322, 494, 10.1056/NEJM199002223220802

Clarke, 2009, Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma, J Clin Oncol, 27, 3861, 10.1200/JCO.2008.20.7944

Brandes, 2004, How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial, Neurology, 63, 1281, 10.1212/01.WNL.0000140495.33615.CA

Eichler, 2007, Multidisciplinary management of brain metastases, Oncologist, 12, 884, 10.1634/theoncologist.12-7-884

Khuong-Quang, 2012, K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas, Acta Neuropathol, 124, 439, 10.1007/s00401-012-0998-0

Park, 2010, Scale to predict survival after surgery for recurrent glioblastoma multiforme, J Clin Oncol, 28, 3838, 10.1200/JCO.2010.30.0582

Brat, 2020, cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas, Acta Neuropathol, 139, 603, 10.1007/s00401-020-02127-9

Hunter, 2012, Treatment of five or more brain metastases with stereotactic radiosurgery, Int J Radiat Oncol Biol Phys, 83, 1394, 10.1016/j.ijrobp.2011.10.026

Wen, 2019, ACTR-30. Updated efficacy and safety of dabrafenib plus trametinib in patients with recurrent/refractory BRAF V600E–mutated high-grade glioma (HGG) and low-grade glioma (LGG), Neuro-oncol, 21, vi19, 10.1093/neuonc/noz175.073

Ostrom, 2019, CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016, Neuro-oncol, 21, v1, 10.1093/neuonc/noz150

Horbinski, 2012, Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas, Neuro-oncol, 14, 777, 10.1093/neuonc/nos077

Giannini, 1999, Pleomorphic xanthoastrocytoma: what do we really know about it?, Cancer, 85, 2033, 10.1002/(SICI)1097-0142(19990501)85:9<2033::AID-CNCR22>3.0.CO;2-Z

Carvalho, 2015, Second-line chemotherapy in recurrent glioblastoma: a 2-cohort study, Oncol Res Treat, 38, 348, 10.1159/000431236

Giannini, 1999, Pleomorphic xanthoastrocytoma: what do we really know about it?, Cancer, 85, 2033, 10.1002/(SICI)1097-0142(19990501)85:9<2033::AID-CNCR22>3.0.CO;2-Z

Kocher, 2011, Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study, J Clin Oncol, 29, 134, 10.1200/JCO.2010.30.1655

Jackson, 2001, Limitations of stereotactic biopsy in the initial management of gliomas, Neuro-oncol, 3, 193, 10.1093/neuonc/3.3.193

Petrelli, 2017, The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: A systematic review and pooled analysis, Eur J Cancer, 84, 141, 10.1016/j.ejca.2017.07.024

Eichler, 2007, Multidisciplinary management of brain metastases, Oncologist, 12, 884, 10.1634/theoncologist.12-7-884

Varshneya, 2016, A national perspective of adult gangliogliomas, J Clin Neurosci, 30, 65, 10.1016/j.jocn.2015.12.028

Vecht, 1993, Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery?, Ann Neurol, 33, 583, 10.1002/ana.410330605

Triebels, 2004, Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas, Neurology, 63, 904, 10.1212/01.WNL.0000137049.65631.DB

Jakola, 2012, Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas, JAMA, 308, 1881, 10.1001/jama.2012.12807

Louis, 2016, The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary, Acta Neuropathol, 131, 803, 10.1007/s00401-016-1545-1

Schouten, 2002, Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma, Cancer, 94, 2698, 10.1002/cncr.10541

Walker, 1978, Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial, J Neurosurg, 49, 333, 10.3171/jns.1978.49.3.0333

Leeper, 2015, IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas, Oncotarget, 6, 30295, 10.18632/oncotarget.4497

Hegi, 2019, MGMT promoter methylation cutoff with safety margin for selecting glioblastoma patients into trials omitting temozolomide: a pooled analysis of four clinical trials, Clin Cancer Res, 25, 1809, 10.1158/1078-0432.CCR-18-3181

Franz, 2014, Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study, Lancet Oncol, 15, 1513, 10.1016/S1470-2045(14)70489-9

Stupp, 2015, Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial, JAMA, 314, 2535, 10.1001/jama.2015.16669

Chamberlain, 2016, Treatment of patients with newly diagnosed glioblastoma, JAMA, 315, 2348, 10.1001/jama.2016.1844

Barker, 1998, Survival and functional status after resection of recurrent glioblastoma multiforme, Neurosurgery, 42, 709, 10.1097/00006123-199804000-00013

McArthur, 2014, Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study, Lancet Oncol, 15, 323, 10.1016/S1470-2045(14)70012-9

Chang, 2017, Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813, Neuro-oncol, 19, 252

Gallo, 2013, Pleomorphic xanthoastrocytoma: long-term results of surgical treatment and analysis of prognostic factors, Br J Neurosurg, 27, 759, 10.3109/02688697.2013.776666

Perry, 2017, Short-course radiation plus temozolomide in elderly patients with glioblastoma, N Engl J Med, 376, 1027, 10.1056/NEJMoa1611977

Roelz, 2016, Residual tumor volume as best outcome predictor in low grade glioma - a nine-years near-randomized survey of surgery vs biopsy, Sci Rep, 6, 32286, 10.1038/srep32286

Soria, 2018, Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer, N Engl J Med, 378, 113, 10.1056/NEJMoa1713137

Brown, 2020, Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: phase III trial NRG Oncology CC001, J Clin Oncol, 38, 1019, 10.1200/JCO.19.02767

Bell, 2020, Comprehensive genomic analysis in NRG Oncology/RTOG 9802: a phase III trial of radiation versus radiation plus procarbazine, lomustine (CCNU), and vincristine in high-risk low-grade glioma, J Clin Oncol, JCO1902983, JCO1902983

Villena Martín, 2020, Metabolic targeting can improve the efficiency of brain tumor biopsies, Semin Oncol, 47, 148, 10.1053/j.seminoncol.2020.04.007

Fisher, 2015, Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424, Int J Radiat Oncol Biol Phys, 91, 497, 10.1016/j.ijrobp.2014.11.012

Brandes, 2003, Carboplatin and teniposide as third-line chemotherapy in patients with recurrent oligodendroglioma or oligoastrocytoma: a phase II study, Ann Oncol, 14, 1727, 10.1093/annonc/mdg494

Sun, 2012, Outcomes of resecting subependymal giant cell astrocytoma (SEGA) among patients with SEGA-related tuberous sclerosis complex: a national claims database analysis, Curr Med Res Opin, 28, 657, 10.1185/03007995.2012.658907

Everhard, 2006, MGMT methylation: a marker of response to temozolomide in low-grade gliomas, Ann Neurol, 60, 740, 10.1002/ana.21044

Lin, 2004, CNS metastases in breast cancer, J Clin Oncol, 22, 3608, 10.1200/JCO.2004.01.175

Brat, 2015, Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas, N Engl J Med, 372, 2481, 10.1056/NEJMoa1402121

Smith, 2008, Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas, J Clin Oncol, 26, 1338, 10.1200/JCO.2007.13.9337

Jiang, 2017, Impact of epidemiological characteristics of supratentorial gliomas in adults brought about by the 2016 world health organization classification of tumors of the central nervous system, Oncotarget, 8, 20354, 10.18632/oncotarget.13555

Herrlinger, 2006, Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03, J Clin Oncol, 24, 4412, 10.1200/JCO.2006.06.9104

Ostrom, 2016, CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009-2013, Neuro-oncol, 18, v1, 10.1093/neuonc/now207

Villena Martín, 2020, Metabolic targeting can improve the efficiency of brain tumor biopsies, Semin Oncol, 47, 148, 10.1053/j.seminoncol.2020.04.007

Caballero, 2012, Prognostic factors for survival in patients treated with stereotactic radiosurgery for recurrent brain metastases after prior whole brain radiotherapy, Int J Radiat Oncol Biol Phys, 83, 303, 10.1016/j.ijrobp.2011.06.1987

Chapman, 2011, Improved survival with vemurafenib in melanoma with BRAF V600E mutation, N Engl J Med, 364, 2507, 10.1056/NEJMoa1103782

Churilla, 2019, Comparison of local control of brain metastases with stereotactic radiosurgery vs surgical resection: a secondary analysis of a randomized clinical trial, JAMA Oncol, 5, 243, 10.1001/jamaoncol.2018.4610

Horbinski, 2013, To BRAF or not to BRAF: is that even a question anymore?, J Neuropathol Exp Neurol, 72, 2, 10.1097/NEN.0b013e318279f3db

Sampson, 2015, Alternating electric fields for the treatment of glioblastoma, JAMA, 314, 2511, 10.1001/jama.2015.16701

Farris, 2017, Brain metastasis velocity: a novel prognostic metric predictive of overall survival and freedom from whole-brain radiation therapy after distant brain failure following upfront radiosurgery alone, Int J Radiat Oncol Biol Phys, 98, 131, 10.1016/j.ijrobp.2017.01.201

Soffietti, 1998, PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas, Neurosurgery, 43, 1066, 10.1097/00006123-199811000-00035

Afra, 1999, Preoperative history and postoperative survival of supratentorial low-grade astrocytomas, Br J Neurosurg, 13, 299, 10.1080/02688699943727

Rusthoven, 2020, Evaluation of first-line radiosurgery vs whole-brain radiotherapy for small cell lung cancer brain metastases: the FIRE-SCLC Cohort Study, JAMA Oncol, 6, 1028, 10.1001/jamaoncol.2020.1271

Chamberlain, 2009, Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma, Cancer, 115, 1734, 10.1002/cncr.24179

Ameratunga, 2018, Anti-angiogenic therapy for high-grade glioma, Cochrane Database Syst Rev, 11, CD008218

Reithmeier, 2010, BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors, BMC Cancer, 10, 30, 10.1186/1471-2407-10-30

Chang, 2010, Analysis of radiosurgical results in patients with brain metastases according to the number of brain lesions: is stereotactic radiosurgery effective for multiple brain metastases?, J Neurosurg, 113, 73, 10.3171/2010.8.GKS10994

Wick, 2010, Bevacizumab and recurrent malignant gliomas: a European perspective, J Clin Oncol, 28, e188, 10.1200/JCO.2009.26.9027

Meyronet, 2017, Characteristics of H3 K27M-mutant gliomas in adults, Neuro-oncol, 19, 1127, 10.1093/neuonc/now274

Chang, 2009, Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial, Lancet Oncol, 10, 1037, 10.1016/S1470-2045(09)70263-3

Maher, 2009, Brain metastasis: opportunities in basic and translational research, Cancer Res, 69, 6015, 10.1158/0008-5472.CAN-08-4347

Walker, 1978, Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial, J Neurosurg, 49, 333, 10.3171/jns.1978.49.3.0333

Kim, 2016, Too little, too soon: short-course radiotherapy in elderly patients with glioblastoma, J Clin Oncol, 34, 2191, 10.1200/JCO.2015.66.3195

Brown, 2020, Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: phase III trial NRG Oncology CC001, J Clin Oncol, 38, 1019, 10.1200/JCO.19.02767

Coburger, 2019, Fluorescence guided surgery by 5-ALA and intraoperative MRI in high grade glioma: a systematic review, J Neurooncol, 141, 533, 10.1007/s11060-018-03052-4

Jakola, 2012, Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas, JAMA, 308, 1881, 10.1001/jama.2012.12807

Buckner, 2016, Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma, N Engl J Med, 374, 1344, 10.1056/NEJMoa1500925

Kaley, 2018, BRAF inhibition in BRAF(V600)-mutant gliomas: results from the VE-BASKET Study, J Clin Oncol, 36, 3477, 10.1200/JCO.2018.78.9990

Eckel-Passow, 2015, Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors, N Engl J Med, 372, 2499, 10.1056/NEJMoa1407279

Stupp, 2015, Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial, JAMA, 314, 2535, 10.1001/jama.2015.16669

Kristensen, 2019, Molecular pathology of tumors of the central nervous system, Ann Oncol, 30, 1265, 10.1093/annonc/mdz164

Tsao, 2018, Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases, Cochrane Database Syst Rev, 1, CD003869

Hawkins, 2011, BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma, Clin Cancer Res, 17, 4790, 10.1158/1078-0432.CCR-11-0034

Moghrabi, 1998, Phase II study of carboplatin (CBDCA) in progressive low-grade gliomas, Neurosurg Focus, 4, e3, 10.3171/foc.1998.4.4.6

Penman, 2015, Current understanding of BRAF alterations in diagnosis, prognosis, and therapeutic targeting in pediatric low-grade gliomas, Front Oncol, 5, 54, 10.3389/fonc.2015.00054

Chamberlain, 2016, Treatment of patients with newly diagnosed glioblastoma, JAMA, 315, 2348, 10.1001/jama.2016.1844

Mok, 2017, Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer, N Engl J Med, 376, 629, 10.1056/NEJMoa1612674

Gallo, 2013, Pleomorphic xanthoastrocytoma: long-term results of surgical treatment and analysis of prognostic factors, Br J Neurosurg, 27, 759, 10.3109/02688697.2013.776666

Nahed, 2015, Management of patients with recurrence of diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline, J Neurooncol, 125, 609, 10.1007/s11060-015-1910-2

Minniti, 2013, Stereotactic radiosurgery in elderly patients with brain metastases, J Neurooncol, 111, 319, 10.1007/s11060-012-1016-z

Karim, 1996, A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844, Int J Radiat Oncol Biol Phys, 36, 549, 10.1016/S0360-3016(96)00352-5

Shaw, 2008, Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial, J Neurosurg, 109, 835, 10.3171/JNS/2008/109/11/0835

Piepmeier, 1996, Variations in the natural history and survival of patients with supratentorial low-grade astrocytomas, Neurosurgery, 38, 872, 10.1097/00006123-199605000-00002

Li, 2017, Prognostic implications of resection extent for patients with glioblastoma multiforme: a meta-analysis, J Neurosurg Sci, 61, 631, 10.23736/S0390-5616.16.03619-5

Hunter, 2012, Treatment of five or more brain metastases with stereotactic radiosurgery, Int J Radiat Oncol Biol Phys, 83, 1394, 10.1016/j.ijrobp.2011.10.026

Tahiri Elousrouti, 2016, Subependymal giant cell astrocytoma (SEGA): a case report and review of the literature, J Med Case Reports, 10, 35, 10.1186/s13256-016-0818-6

Kazmi, 2019, Re-irradiation for recurrent glioblastoma (GBM): a systematic review and meta-analysis, J Neurooncol, 142, 79, 10.1007/s11060-018-03064-0

Chang, 2008, Seizure characteristics and control following resection in 332 patients with low-grade gliomas, J Neurosurg, 108, 227, 10.3171/JNS/2008/108/2/0227

Shaw, 2012, Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802, J Clin Oncol, 30, 3065, 10.1200/JCO.2011.35.8598

Banfill, 2012, Stereotactic radiosurgery for the treatment of brain metastases: impact of cerebral disease burden on survival, Br J Neurosurg, 26, 674, 10.3109/02688697.2012.690913

Meyronet, 2017, Characteristics of H3 K27M-mutant gliomas in adults, Neuro-oncol, 19, 1127, 10.1093/neuonc/now274

Brandes, 2003, Carboplatin and teniposide as third-line chemotherapy in patients with recurrent oligodendroglioma or oligoastrocytoma: a phase II study, Ann Oncol, 14, 1727, 10.1093/annonc/mdg494

Friedman, 2009, Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma, J Clin Oncol, 27, 4733, 10.1200/JCO.2008.19.8721

van den Bent, 2005, Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial, Lancet, 366, 985, 10.1016/S0140-6736(05)67070-5

Wick, 2010, Bevacizumab and recurrent malignant gliomas: a European perspective, J Clin Oncol, 28, e188, 10.1200/JCO.2009.26.9027

Varshneya, 2016, A national perspective of adult gangliogliomas, J Clin Neurosci, 30, 65, 10.1016/j.jocn.2015.12.028

Bhatnagar, 2006, Stereotactic radiosurgery for four or more intracranial metastases, Int J Radiat Oncol Biol Phys, 64, 898, 10.1016/j.ijrobp.2005.08.035

Panageas, 2012, Initial treatment patterns over time for anaplastic oligodendroglial tumors, Neuro-oncol, 14, 761, 10.1093/neuonc/nos065

Wick, 2017, Lomustine and bevacizumab in progressive glioblastoma, N Engl J Med, 377, 1954, 10.1056/NEJMoa1707358

Houillier, 2010, IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas, Neurology, 75, 1560, 10.1212/WNL.0b013e3181f96282

Indelicato, 2019, Outcomes following proton therapy for pediatric low-grade glioma, Int J Radiat Oncol Biol Phys, 104, 149, 10.1016/j.ijrobp.2019.01.078

Mistry, 2015, BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma, J Clin Oncol, 33, 1015, 10.1200/JCO.2014.58.3922

Everhard, 2006, MGMT methylation: a marker of response to temozolomide in low-grade gliomas, Ann Neurol, 60, 740, 10.1002/ana.21044

Kesari, 2009, Phase II study of protracted daily temozolomide for low-grade gliomas in adults, Clin Cancer Res, 15, 330, 10.1158/1078-0432.CCR-08-0888

Akyurek, 2007, Stereotactic radiosurgical treatment of cerebral metastases arising from breast cancer, Am J Clin Oncol, 30, 310, 10.1097/01.coc.0000258365.50975.f6

Wahl, 2017, Probing the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low-grade gliomas, Cancer, 123, 4631, 10.1002/cncr.30909